Want to see CYTK full AI Analyst Report?
Cytokinetics (CYTK) AI Stock Analysis
Cytokinetics
(NASDAQ:CYTK)
CYTK’s score is constrained primarily by weak financial performance (sharp TTM revenue decline, very large losses, heavy cash burn, and a pressured capital structure with negative equity and high debt). Technicals also show a downtrend with negative momentum indicators. Offsetting these, the earnings call highlighted strong commercial launch traction, positive pivotal data and clear regulatory milestones, plus materially improved liquidity from the recent financing; valuation is difficult to support given negative earnings and no dividend.
Cytokinetics Key Performance Indicators (KPIs)
Revenue by SegmentHighlights revenue contributions from different business segments, providing insight into which areas drive growth and how diversified the company’s income streams are.
Historically Cytokinetics’ top line was lumpy—license and milestone receipts drove episodic spikes while product revenue was essentially zero until Q1 2026. The ~$4.8M of net product revenue plus a Bayer milestone mark the start of recurring commercial income and are backed by encouraging early prescribing, but access is still scaling and Acacia HCM safety observations plus heavy launch/SG&A spend mean near‑term volatility; sustainable upside hinges on payer parity, expanded prescriber uptake, and upcoming regulatory readouts.
The FlyCytokinetics (CYTK) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.62B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.89M
- Price to Earnings (P/E)
- -8.6
- Beta (1Y)
- 0.86
- Revenue Growth
- -21.07%
- EPS Growth
- -41.03%
- Country
- US
- Employees
- 673
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cytokinetics Business Overview & Revenue Model
Company Description
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
How the Company Makes Money
Cytokinetics primarily makes money through biopharmaceutical collaboration economics rather than broad product sales, as it has historically been a development-stage company. Its revenue model centers on (1) collaboration and license arrangements wit...
Cytokinetics Earnings Call Summary
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
On the call Cytokinetics updated full‑year 2026 financial guidance, raising GAAP combined R&D and SG&A to $860–$890 million (from $830–$870M) with stock‑based compensation now forecast at $130–$140 million (up from $120–$130M); excluding SBC the combined range is $720–$760M. They closed Q2 with ~ $1.7 billion in cash and investments (vs. $1.1B at Q1) after a May public offering that generated ~ $760M net proceeds, and reiterated commercial milestones including an sNDA submission for aficamten in nHCM planned for Q4 2026 and a MAPLE‑HCM sNDA PDUFA date of November 14, 2026. Operational access targets include preparing a UK launch in Q4, pursuing broader European rollouts (additional launches into early 2027), and achieving payer parity by year‑end 2026 (nearly 90% Medicare parity today; >50% commercial coverage now). They also guided clinical program timing: continued COMET enrollment through 2026, completion of AMBER‑HFpEF Cohort 1 enrollment in H2 2026, ongoing CEDAR adolescent cohort work, and potential Health Canada action in H2 2026.
Cytokinetics Financial Statement Overview
Summary
Financial statements indicate a high-burn, loss-making profile: TTM revenue is down sharply (-32.94%), losses remain very large (TTM net margin -13.21%; EBIT margin -9.39%), and cash burn is heavy (TTM operating cash flow -$700.9M; free cash flow -$732.1M). The balance sheet is also pressured by negative shareholder equity (TTM -$173.5M) and high total debt (~$1.02B), increasing financing risk despite strong gross margins.
Income Statement
24NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.96M | 88.04M | 18.47M | 7.53M | 94.59M | 70.43M |
| Gross Profit | 62.98M | 77.91M | -320.93M | -322.59M | -146.22M | -89.51M |
| EBITDA | -821.80M | -774.83M | -493.48M | -456.68M | -331.99M | -183.71M |
| Net Income | -894.00M | -784.96M | -589.53M | -526.24M | -388.95M | -215.31M |
Balance Sheet | ||||||
| Total Assets | 1.92B | 1.42B | 1.40B | 824.32M | 1.01B | 841.32M |
| Cash, Cash Equivalents and Short-Term Investments | 1.17B | 882.22M | 1.08B | 614.82M | 782.58M | 471.64M |
| Total Debt | 1.27B | 1.28B | 788.68M | 755.77M | 750.30M | 269.93M |
| Total Liabilities | 2.10B | 2.08B | 1.54B | 1.21B | 1.12B | 597.46M |
| Stockholders Equity | -173.49M | -659.63M | -135.37M | -386.32M | -107.90M | 243.86M |
Cash Flow | ||||||
| Free Cash Flow | -580.71M | -534.82M | -399.80M | -415.75M | -310.85M | -191.39M |
| Operating Cash Flow | -555.45M | -510.01M | -395.89M | -414.33M | -299.52M | -142.52M |
| Investing Cash Flow | -503.68M | 16.67M | -553.10M | 239.25M | -262.13M | -147.78M |
| Financing Cash Flow | 1.24B | 524.46M | 930.61M | 221.32M | 516.17M | 319.98M |
Cytokinetics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTK, the sentiment is Negative. The current price of 62.31 is below the 20-day moving average (MA) of 62.35, below the 50-day MA of 66.91, and below the 200-day MA of 70.07, indicating a bearish trend. The MACD of -1.23 indicates Negative momentum. The RSI at 43.94 is Neutral, neither overbought nor oversold. The STOCH value of 50.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYTK.
Cytokinetics Risk Analysis
Cytokinetics disclosed 35 risk factors in its most recent earnings report. Cytokinetics reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksCytokinetics Peers Comparison
Overall Rating
SRPT58Neutral
PTCT56Neutral
EWTX53Neutral
SRRK50Neutral- CYTK49Neutral
DYN47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SRPT | 58Neutral | $1.94B | -12.88 | -9.96% | ― | -20.44% | -349.84% |
| PTCT | 56Neutral | $5.09B | -52.00 | 57.10% | ― | -35.05% | -113.73% |
| EWTX | 53Neutral | $4.14B | -20.37 | -39.01% | ― | ― | -18.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SRRK | 50Neutral | $5.23B | -13.29 | -160.19% | ― | ― | -14.40% |
| CYTK | 49Neutral | $8.62B | -8.64 | 163.98% | ― | -21.07% | -41.03% |
| DYN | 47Neutral | $3.23B | -5.42 | -64.30% | ― | ― | 13.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CYTK | Cytokinetics | 62.31 | 3.12 | 5.27% | |
| SRPT | Sarepta Therapeutics Inc. | 18.54 | -0.13 | -0.70% | |
| PTCT | PTC Therapeutics | 68.12 | -3.65 | -5.09% | |
| SRRK | Scholar Rock Holding | 43.98 | 15.99 | 57.13% | |
| DYN | Dyne Therapeutics, Inc. | 18.05 | -2.85 | -13.64% | |
| EWTX | Edgewise Therapeutics, Inc. | 37.68 | 20.31 | 116.93% |
Cytokinetics Corporate Events
Cytokinetics Reports Positive Phase 3 Aficamten HCM Results
PositiveOn August 28, 2026, Cytokinetics reported positive primary results from its pivotal Phase 3 ACACIA-HCM trial of aficamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy, presented at the ESC Congress 2026 and published in The...
Cytokinetics Files Patent Suit to Protect MYQORZO Franchise
NegativeOn August 13, 2026, Cytokinetics filed a complaint in the U.S. District Court for the District of Delaware against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the pa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026